Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Short term Debt (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 5 years of Short term Debt data on record, last reported at $29.0 million in Q4 2025.

  • For Q4 2025, Short term Debt rose 61.11% year-over-year to $29.0 million; the TTM value through Dec 2025 reached $29.0 million, up 61.11%, while the annual FY2025 figure was $29.0 million, 61.11% up from the prior year.
  • Short term Debt reached $29.0 million in Q4 2025 per INDV's latest filing, up from $18.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $29.0 million in Q4 2025 and bottomed at $3.0 million in Q4 2021.
  • Average Short term Debt over 5 years is $13.8 million, with a median of $18.0 million recorded in 2024.
  • Peak YoY movement for Short term Debt: changed 0.0% in 2022, then soared 500.0% in 2024.
  • A 5-year view of Short term Debt shows it stood at $3.0 million in 2021, then changed by 0.0% to $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023, then skyrocketed by 500.0% to $18.0 million in 2024, then soared by 61.11% to $29.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $29.0 million in Q4 2025, $18.0 million in Q3 2025, and $18.0 million in Q2 2025.